Search Results

You are looking at 41 - 50 of 179 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Rodrigo Goncalves and Ron Bose

that the Onco type DX score predicted the likelihood of distant recurrence or breast cancer death when treated with hormonal therapy alone. 8 , 9 Archival samples from the NSABP B-14 trial, which tested the use of tamoxifen in patients with estrogen

Full access

Gayathri Nagaraj and Cynthia X. Ma

literature. Although the proportional risk reduction from adjuvant polychemotherapy was found to be independent of ER status and tamoxifen use in the Oxford overview, 3 the relative chemoresistance of ER+ disease has been demonstrated in the neoadjuvant

Full access

Lee S. Schwartzberg and Sarah L. Blair

receiving breast-conserving surgery without RT versus mastectomy, and 6 times higher for those receiving tamoxifen for less than 1 year compared with 5 years or more. 8 However, based on a prospective randomized clinical trial, carefully selected patients

Full access

Parijatham S. Thomas

(SERMs) and aromatase inhibitors (AIs) for the prevention of breast cancer. The Breast Cancer Prevention Trial (BCPT) evaluated 13,388 women aged ≥35 years with an elevated risk of breast cancer randomized to tamoxifen daily for 5 years or placebo

Full access

Shaneli A. Fernando and Stephen B. Edge

adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group . J Clin Oncol 1999 ; 17 : 1689 – 1700 . 3. Jagsi R Raad RA Goldberg S . Locoregional recurrence rates and prognostic

Full access

John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud, and Joan M. Neuner

Background Aromatase inhibitors (AIs), tamoxifen, and the sequential use of these agents are all standard options for adjuvant hormonal therapy (HT) for postmenopausal women with early-stage, estrogen receptor (ER)–positive breast cancer. At

Full access

Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag, and Rinaa S. Punglia

had positive margins (3%); 31% were high grade. HR status was positive in 49%, but was missing in 42% of cases. Most women (83%) received RT for their initial DCIS; only 40% received AET. Of AET recipients, most (92%) took tamoxifen, 5% took an

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

tumor was ER+ and/or PR+—tamoxifen. In the past decade, this approach was challenged by several findings. In 1998, a pivotal trial convincingly showed the clinical importance of tyrosine kinase signal transduction pathways by demonstrating that

Full access

Adrienne G. Waks and Ann H. Partridge

cohorts. In women treated for hormone receptor–positive early-stage breast cancer, multiple studies demonstrate an association between tamoxifen use and persistence of postchemotherapy amenorrhea. 12 , 19 , 20 Rather than representing a gonadotoxic effect

Full access

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff, and Hannah M. Linden

lack of an accessible nonbone site of metastasis and patient refusal. She was treated with tamoxifen and bisphosphonate therapy with symptomatic improvement, with decline in tumor extent as measured by MRI and FDG-PET ( Figure 1, C ). Because of